Effect of a synthetic polypeptide (Cop 1) on patients with multiple sclerosis and with acute disseminated encephalomyelitis
- 1 April 1977
- journal article
- research article
- Published by Elsevier BV in Journal of the Neurological Sciences
- Vol. 31 (3), 433-438
- https://doi.org/10.1016/0022-510x(77)90220-9
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- INTENSIVE IMMUNOSUPPRESSION IN THE TREATMENT OF MULTIPLE SCLEROSISThe Lancet, 1974
- Cellular Hypersensitivity to Basic Myelin (A1) Protein and Clinical Multiple SclerosisNew England Journal of Medicine, 1974
- Cell‐mediated immunity to myelin basic protein in acute disseminated encephalomyelitisNeurology, 1974
- Myelin Basic Protein Administration in Multiple SclerosisArchives of Neurology, 1973
- Failure of antilymphocytic globulin therapy in chronic progressive multiple sclerosisNeurology, 1973
- Multiple Sclerosis Unaffected by Azathioprine in Pilot StudyArchives of Neurology, 1973
- Suppression of experimental allergic encephalomyelitis by chemically modified encephalitogenImmunochemistry, 1972
- Basic encephalitogenic protein: A simplified purification on sulphoethyl‐sephadexFEBS Letters, 1970
- Cooperative study in the evaluation of therapy in multiple sclerosisNeurology, 1970
- Experimental Allergic Encephalomyelitis and Autoimmune DiseaseAdvances in Immunology, 1966